POLB — Poolbeg Pharma Share News
0.000.00%
- £64.50m
- £52.33m
REG - Poolbeg Pharma PLC - POLB 001 Oncology Programme Update Meeting
AnnouncementRCS - Poolbeg Pharma PLC - SAB Endorses Influenza Drug Targets
AnnouncementREG - Poolbeg Pharma PLC - Poolbeg Partners with a Nasdaq-Listed Biopharma
AnnouncementREG - Poolbeg Pharma PLC - Favourable Conclusion of Patent Opposition
AnnouncementRCS - Poolbeg Pharma PLC - Immunomodulator I Patent Portfolio Strengthened
AnnouncementREG - Poolbeg Pharma PLC - Immunomodulator I Patent Opposition Withdrawal
AnnouncementREG - Poolbeg Pharma PLC - Interim results for the six months to 30 June 2023
AnnouncementREG - Poolbeg Pharma PLC - AI led programme identifies influenza drug targets
AnnouncementREG - Poolbeg Pharma PLC - Oral Vaccine Programme Moves Forward
AnnouncementREG - Poolbeg Pharma PLC - Board Appointment
AnnouncementREG - Poolbeg Pharma PLC - Results of Annual General Meeting
AnnouncementREG - Poolbeg Pharma PLC - Annual Report & AGM Notice
AnnouncementREG - Poolbeg Pharma PLC - Results for the year ended 31 December 2022
AnnouncementREG - Poolbeg Pharma PLC - Notification of Major Holdings
AnnouncementREG - Poolbeg Pharma PLC Schroders PLC - Notification of Major Holdings
AnnouncementRCS - Poolbeg Pharma PLC - POLB 001 patent portfolio strengthened
AnnouncementREG - Poolbeg Pharma PLC - Price Monitoring Extension
AnnouncementREG - Poolbeg Pharma PLC - Second Price Monitoring Extn
AnnouncementREG - Poolbeg Pharma PLC - Positive Results POLB001 LPS Human Challenge Trial
Announcement